Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Biocon Completes Biologics Stake Acquisition from Mylan

Synopsis:


Biocon Limited completed the acquisition of 7.18 crore equity shares of Biocon Biologics from Mylan Inc for $200 million on January 21, 2026, increasing its holding to nearly 98 percent on a fully diluted basis.


Source:
Biocon Limited Press Release (NSE Exchange Filings) | Published on Jan 21, 2026

Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.y

As quoted in the press release from Biocon Limited (NSE Exchange Filings), the company has completed the acquisition of the remaining equity shares of Biocon Biologics Limited from Mylan Inc. The transaction involved the purchase of 7.18 crore equity shares for a cash consideration of $200 million. Following this transaction, Biocon Limited now holds approximately 98 percent of the paid-up equity share capital of Biocon Biologics on a fully diluted basis.

The disclosure to the stock exchanges was made in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The filing confirms that the acquisition occurred on January 21, 2026, and is included as part of the company's continuing statutory disclosures to BSE and NSE.

This acquisition represents the final tranche of a previously approved transaction. The Board of Directors had earlier approved the acquisition of 14.36 crore equity shares of Biocon Biologics from Mylan Inc for a total cash consideration of $400 million. The earlier tranche of 7.18 crore shares was completed before this final transaction.

Also Read: Lemon Tree Hotels Signs Premier Omkareshwar Property in Madhya Pradesh

Biocon Limited

Trade

366.2-6.79 (-1.82 %)

Updated - 23 January 2026
375.80day high
DAY HIGH
365.15day low
DAY LOW
1896911
VOLUME (BSE)

Key Takeaway

  • Biocon Limited completed the acquisition of 7.18 crore equity shares of Biocon Biologics

  • The shares were acquired from Mylan Inc for $200 million in cash

  • The transaction was completed on January 21, 2026

  • Post-acquisition holding stands at approximately 98 percent on a fully diluted basis

  • The disclosure was filed under Regulation 30 with BSE and NSE

Details of the Share Acquisition

Biocon Biologics Limited is an unlisted material subsidiary of Biocon Limited. Once the transaction was completed, Biocon Limited was able to effectively consolidate a considerable amount of its equity in the subsidiary, which comprises equity shares donated to Mylan Inc through another company or entity, as part of a more extensive shareholding structure.

According to the exchange filing, the acquisition was executed through cash consideration. This filing did not include any adjustments to the original transaction value as stated in the Agreement and Plan of Merger; however, the Company stated that the additional information would also be posted as part of the Company's routine regulatory communications on its website.

This transaction is in line with the previously reported Board resolution on December 6, 2025, and the disclosures of the partial completion of the acquisition made in early January 2026. The final round of disclosures on January 21 confirms that all required approvals have been received.

Summary of the Biocon Biologics Acquisition

Details And Specifics

Information

Equity shares acquired

7.18 crore equity shares

Seller and consideration

Mylan Inc. for $200 million

Acquisition completion date

January 21, 2026

Post-acquisition holding

98 percent on a fully diluted basis

Regulatory disclosure

Regulation 30, SEBI LODR

Regulatory Filing and Compliance

Biocon Limited has confirmed that the filing meets all regulatory requirements set out in Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company submitted the filing to the BSE Limited (BSE) and to the National Stock Exchange of India Ltd (NSE). 

The Joint Company Secretary and Compliance Officer of Biocon Ltd signed the filing. The filing did not contain any forward-looking statements, financial projections or changes to any current regulatory approvals.

Biocon Share Price Update

Biocon's share price data were reported on the National Stock Exchange on January 21, 2026. As of 15:30 PM IST, the Biocon share price stood at Rs. 365.00. The stock recorded a decline of 0.50 percent compared with the previous close.

During the trading session, the stock moved between an intraday high of Rs. 370.05 and an intraday low of Rs. 359.05. The previous closing price was Rs. 366.85, while the closing price for the session was Rs. 364.85. The reported data reflects exchange-published information available at the stated time.

Also Read: CESC Green Power Signs ₹3,800 Cr MoU for Solar Cell & Power Projects

Published Date : 22 Jan 2026

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.8 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,900+ Cr MTF Book

icon-with-text